Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
robin, yes, I can call them Tues. Also, maybe DF King may know? I'll email them to ask.
robin, I recall someone commenting about why the meeting isn't being held at the address listed in the proxy cause it's just a desk with a phone. Someone posted the street where the meeting will be held and questioned why it was being held at a hotel not far from the address listed, 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, Ireland. I guess a call to the local hotels will disclose if the meeting will be held in their hotel meeting room......just sayin
onerage, maybe the proxy for Sarissa could be an attorney. I don't know if PWO will open the meeting but it states in the proxy that shareholders who attend the meeting they get one vote etc. based on the wording legally they can't refuse people from attending. I think that's why they eventually let Liam inside last year.
I've had experience with annual proxy meetings for another company and we opened the doors to everyone who attended along with a list of the shareholders available at the entrance for other shareholders to view. But that was many moons ago. Times changed especially under the current circumstances.
robin, how close are you to the location of the meeting? Last year LaimLinden attended the meeting and based on the way he was treated it didn't sound very pleasant I would check to ask if the public would be admitted to the meeting room. Wow, that would be amazing if they let you inside.
capt, ditto
Nuke, ok makes sense. So the question is who will know the outcome first. Amarin will probably know first I doubt if Sarissa will be at the general meeting.
We should ask Liamlindem if he plans on attending? He can post results. Lol
nuke/bird. keep in mind. The meeting is scheduled to start at 3pm Dublin time. Let's assume it lasts about an hour and they determine the results and prepare a PR which will take a few hrs to pass it by legal. So if we're lucky we'll know the next day. I'm looking forward to watching the opening the next day. Hopefully, it'll be on the upside.
Birdrock, amarin will know the final count some time on the 28th but will we? I'll bet not.
Birdrock, somehow I get the feeling you know the routine. Just wondering how many yrs of experience you have in the HF bus.
birdrock/robin. In the footnotes of the form 4's you will note that KM and JT stand to make a bloody fortune. I think it's somewhere around 3plus million shs will vest if the company is sold. So KM will hang around as long as Sarissa will have him. It's been mentioned on this board that KM probably wishes PWO will be gone. Who knows what kind of constraints he has put on KM.
monk, wow that's crazy. Maybe you should report it to DF King via email so the management will read it.
birdrock, so in other words Sarissa will disclose publicly the results prior to Amarin if they get results first?
robin, at this juncture, since Amarin is the public company I would think the attorneys representing both entities would coordinate the release.
A little bit of trivial info that happened when HLS was approached by PFE to collaborate on the sales agreement, I called Amarin to as why they didn't PR the news which I thought would be an uptick for the company. The IR person said in not a nice reply it's not up to us to PR the news that's between HLS and PFE. Well, now Amarin always includes that information when it applies. They are the worst company to work with.
birdrock, so it appears there's a window of 2 to 4 days. Or according to my source at DF King "as soon as practical-with 3 days.
So we should expect results late Friday night. If bad news for Amarin really late on Friday but good news for Sarissa we could know the results sooner. Or they will wait for Monday 6 a.m. March 6 to PR results. LOL
Raf, actually it'll be difficult to call since there are so many proposals and some will vote for a few new board members and others will go straight down column A for the blue wave.
birdrock, is there a rule somewhere? This is different than the usual proxy meeting. I just asked someone who would know for sure. Certain filings for material events have 10 days to report and file an 8K.
rosemount, One more business day for the votes to be counted. I can't wait to see what the last day will bring from both parties. What's going to be interesting is the final count and then amarin is due to release their year end financials. They still haven't announced the date, I suspect they will wait the full 90 days before releasing the numbers which would bring them to march 31.
I'm wondering how many days they have to release the final numbers after the Feb 28 GM. I hope they're not going to wait till they file their 10K to release the results of the vote.
I'll ask someone if there's a final due date for the public to find out who won the proxy contest.
Raf, Just another truth seeker. WTH are they talking about? I wonder which nut job journalist wrote that garbage?
Tal, Thanks for the detailed research. Now I'm in the depressed stage of grieving. LOL
On a serious note Laurent posted a cartogram please note the date is 20-21. If the UK budget posted is outdated I can't imagine how much worse it would be with the currently updated budgeting allocations. Maybe eventually Vazkepa will enter the third and final phase of approval in 2025.
Raf, scary=PD=psycho Dude
Thanks for refreshing my memory I recall the switch. Very strange
retinadoc, guess where the former CFO, Michael Kalb, went to work after he left Amarin same company where JT is on the board Cincor (CINC). Astra Zeneca announces they're buying CINC for $26 in Jan 2023. At the time of the announcement, it was 206% premium.
James Healy who's on the board of Sofinnova is the CEO of CINC. He was one of the original founders and financial backers of Amarin.
Going back a few years ago before PWO came into town and Lars Ekman was still COB the cookies started to crumble. Fast forward BB is out of the stock and so is the old guard. I'm more convinced than ever Sarissa needs to win this proxy fight. I think the old guard saw this coming.
onerag, well stated. For those of you who work in any type of professional arena know the value of networking. Sarissa certainly has the required network to get the door open to BP negotiations when the time is right. But in the meantime, he needs to restructure the company. It may take time but with a professional at the helm, I'm willing to wait.
Raf, wow been there done that one too many times in my life. I experienced the sinking feeling in the pit of my stomach on 3/30/20 when the news hit the tape and I was preoccupied down sizing. So stressful as I too moved through the grieving process similar to losing a spouse. The word that comes to mind is blindsided.
Sarissa is our only hope. Especially after watching the webinar rerun and witnessing the attitude PWO projected. Crumpy old man.
Tal, just a tiny technicality poordude overlooked.
I'm convinced more than ever that we will not see any significant revenues in the EU for several years. If I could just knock on all the doors of the shareholders that haven't voted and provide a fact sheet of all the blunders amarin has made over the past couple years I'll be able to sleep between now and Feb 28.
Raf, I actually gave poordude the benefit of the doubt a few times when he attacked me but overlooked it. The straw that broke the camel's back was his last insult. I finally had to put him on ignore. Maybe he started using the pills he pushes.
Go Big Blue!!!
Thank heavens we have only 2 more business days till this BS stops.
Amarin Urges Shareholders To Vote "Against" Sarissa's Harmful Proposals At Upcoming General Meeting Says 'It Has No Plan, No New Ideas And An Underqualified Slate'
BENZINGA 9:04 AM ET 2/17/2023
Symbol Last Price Change
AMRN 1.87up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/16/2023
The NEW Amarin and NEW Board is On the Right Track - Leading Independent Experts, ISS and Glass Lewis, Agree that Sarissa Representation is Not Warranted
Sarissa's Misguided Campaign to Remove Amarin's Chairman and Gain De Facto Board Control Would be Detrimental to Shareholder Value
Sarissa Continues to Spread Misinformation at the Expense of All Amarin Shareholders in its Self-Serving Attempt to Get on the Board
Deadline to Submit Votes for ADS Holders is 3 PM GMT (10 AM ET) on February 22, 2023, and 3 PM GMT (10 AM ET) on February 24, 2023, for Holders of Ordinary Shares
DUBLIN, Ireland and BRIDGEWATER, N.J. , Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Amarin Corporation plc(NASDAQ:AMRN) ("Amarin" or the "Company") Board of Directors today issued the following statement reiterating to shareholders its recommendation to vote on the WHITE proxy card "AGAINST" all of Sarissa's harmful proposals ahead of the General Meeting of Shareholders, which is scheduled to be held on February 28, 2023. Shareholders of record as of January 23, 2023, will be entitled to vote at the meeting. For ADS holders, the deadline to submit votes is 3 PM GMT (10 AM ET) on February 22, 2023, and for holders of ordinary shares, the deadline is 3 PM GMT (10 AM ET) on February 24, 2023.
The Amarin Board has one critical message for our shareholders: Amarin is at an inflection point, where upcoming pricing and reimbursement negotiations and decisions will chart the future for the Company, including ensuring M&A is a viable option. Our refreshed Board are the change agents the Company needs and have actively positioned the business to turn Amarin around and drive near- and long-term value.
As leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co ("Glass Lewis") recognized in their vote recommendations for Amarin's WHITE proxy card "AGAINST" Sarissa's proposals, the new and refreshed Board has already made significant changes over the last 18 months. Meanwhile, Sarissa has failed to make a compelling case for change. ISS and Glass Lewis's recommendations are important third party endorsements that Amarin has the RIGHT strategy, RIGHT team and RIGHT Board to drive near- and long-term value. Here is why:
Critical expertise is needed and already on the Board today. Our Board is intimately involved in pricing and reimbursement discussions, including Chairman Per Wold-Olsen. Depriving the Company of essential advice and experience - by removing Mr. Wold-Olsen and adding seven underqualified candidates who have little to no expertise in this area - would be detrimental. Theoretical "shareholder representation" will not make up for this massive loss of experience and practical know-how. Additionally, nearly doubling the size of the Board for a company of our size does not make sense, and if anything, would put the Company at risk at a critical time.
Mr. Wold-Olsen is an essential guiding force. He has brought his wealth of experience to bear in every area of Amarin's business. Mr. Wold-Olsen has direct relationships with European regulators that he is leveraging to benefit Amarin as we navigate the complexities of pricing and reimbursement negotiations and he works directly with management daily, demonstrating his unwavering commitment to Amarin's success. The future of Amarin hinges on its ability to negotiate successful pricing in Europe - and Mr. Wold-Olsen is central to this effort. Sarissa is not.
Amarin's Board is superior to Sarissa's slate in every critical area. Amarin's refreshed Board brings more than 260 years of critical expertise across international, in particular European, cardiovascular and related product launches, and healthcare investment which has been vital to Amarin's early success. Sarissa's underqualified nominees, on the other hand, collectively lack critical understanding of operating a pharma company and have minimal experience with European drug launches, pricing and reimbursement and commercial expertise.
Amarin has taken proactive and decisive action to succeed and drive value. The refreshed Board, alongside the new management team, have taken swift and proactive action. These steps have contributed to substantial progress in a short period of time across all facets of the business - strategic, operational and financial - and are reflected in Amarin's performance in 2022 and early 2023.
Sarissa has an abysmal track record. We understand our shareholders' frustration with Amarin's stock price today, but it is critical that our shareholders consider the facts when Sarissa is on boards:
Median total shareholder return ("TSR") at companies during the tenure of Sarissa nominated directors is NEGATIVE 24%1
Companies that Sarissa excluded from its presentation have a median TSR of a staggering NEGATIVE 59%1
In four instances, companies with Sarissa nominated directors LOST OVER 75% of their value1
The Amarin Board has been and continues to be 100% focused on advancing all of our shareholders' best interests. Sarissa, on the other hand, purposefully provides shareholders with misinformation as part of its transparent attempt to do anything to get on the Board. Sarissa is only focused on serving its own self-interest at the expense of all Amarin shareholders. If Sarissa cannot be trusted to provide shareholders with the truth, why should it be trusted as a steward of shareholder value creation? The current Amarin Board is best equipped to guide the NEW Amarin and maximize shareholder value.
We strongly urge all shareholders to consider what is at stake and vote "AGAINST" Sarissa's harmful proposals on the WHITE proxy card.
With Amarin's February 28 General Meeting fast approaching, it is extremely important that you vote as soon as possible, no matter how many shares you own. Shareholders can switch their vote at any time by simply voting on the WHITE proxy card "AGAINST" all of Sarissa's harmful proposals. Only the latest-dated proxy counts.
Amarin shareholders who need assistance in voting their shares may call Amarin's proxy solicitors: Morrow Sodali at (800) 662-5200 (toll-free) or (20
tat, the Edding IPO filing has been rejected a few times. They've tried to get listed on the Hong Kong exchange but they have very stringent requirements the exchange claims they're trying to lighten up on the listing requirements. Each rejection causes them to go back to the drawing board to update their financials. Edding cannot afford to follow up with Amarin's agreement as they don't have the financial wherewith all to pull it off.
RMB, China will NEVER happen. Why don't people accept the fact that China is BS? Amarin signed an agreement which Edding in 2015. We are currently in the year 2023. 8 years later...people think about it and then get back to me with a realistic/logical answer. What happened to all the MENA region? Amarin had roughly $300,000 in 6 years. Last 3Q filing it was zero. Now it's not even mentioned. KM is a salesman with a line of BS.
here you go peeps.
Sarissa Capital Blasts Amarin’s Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board
BUSINESS WIRE 4:05 PM ET 2/16/2023
Symbol Last Price Change
AMRN 1.87up -0.03 (-1.5789%)
QUOTES AS OF 04:00:00 PM ET 02/16/2023
Sarissa is Confident that Long Suffering Amarin Shareholders Will Make Up Their Own Minds and Vote “FOR” Change at Amarin(AMRN)
GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc(AMRN) :
Sarissa Capital is outraged but not surprised by Amarin’s repeated false statements intended to mislead shareholders and switch votes away from Sarissa. Amarin(AMRN) has made these false statements throughout this proxy contest, including in its evaluation of the company’s progress and its own performance, in its characterizations of the board’s interactions with Sarissa, and, most recently, in the failure of its registrar to be properly instructed. Clearly, Amarin(AMRN) is willing to say anything to keep Sarissa, its largest shareholder, off the board.
Sarissa is confident that fellow long-suffering shareholders see through the ploys and will vote “FOR” necessary change. We shareholders know the truth as we have lived through the nightmarish reality under the current regime which resulted in a tremendous destruction of shareholder value and an imperiled European launch. Sarissa urges all shareholders to ignore the false statements and empty promises made by Amarin(AMRN) and make up their own minds.
Amarin (AMRN) is in dire need of change. Sarissa is Amarin’s largest shareholder, owning more than 25 million shares. We are long term shareholders and have not sold any shares since acquiring our position. We have an exceptional track record of success, including in the cardiovascular space, and we believe our nominees have the experience and qualifications to help unlock Amarin’s true potential.
You can vote on the blue proxy card or the white proxy card but if you want to fully support Sarissa, you must make sure that all “FOR” boxes are marked on your proxy card (blue or white) before you submit it.
If you have any questions on how to vote, we recommend that you contact Sarissa’s proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing AMRN@dfking.com.
We urge all shareholders to vote “FOR” the Sarissa Nominees and “FOR” the removal of Chairman Per Wold-Olsen on or prior to the deadline on Tuesday, February 21, 2023.
Visit our website at www.freeamarin.com for helpful information about Sarissa and the need for change at Amarin(AMRN).
IF YOU ALREADY VOTED “FOR” ALL PROPOSALS AND SUBMITTED YOUR BLUE PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA’S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.
The General Meeting of Amarin(AMRN) shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023.
Additional Information
Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc(AMRN) (the “Company”) at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the “General Meeting”). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.
The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).
#FreeAmarin
jroon, omg you have no idea what I went through to get my sister to understand the importance of voting. Then trying to walk her through the process needless to say was very confusing. She never received a blue proxy so we used the white card and voted FOR all proposals.
I'm hoping we'll see additional PR from either DF King or Sarissa urging shareholders to Vote BLUE
seve, honestly IMO they all should be counted since most of the votes are done electronically. At the last proxy vote when Sarissa advise voters to abstain there were a surprising amount of broker non-votes. Hopefully with all the PR they'll wake up and smell the coffee.
seve, I suspect that DF King is on top of the incoming votes but anything can happen between now and 2/22/23.
Amarin still hasn't confirmed when they will release their ye 2022 financials. They have till the end of March provided they don't ask for an extension.
birdrock, paid shills. I'm not familiar with Joele Frank's name but that doesn't mean anything. Does he/she have a name in the street?
birdrock, so the deal is Amarin solicits both of them independently to debate the Sarissa statement and since they're getting paid they don't care how much disinformation they release. Dirtbags
ggwpq, you can count on Sarissa releasing another rebuttal. What really pisses me off is how much money they are squandering trying to win over anyone who hasn't voted.
birdrock, are Glass Lewis/ISS one in the same?
https://www.whitecase.com/insight-alert/iss-and-glass-lewis-issue-2022-updates-top-six-key-policy-changes-and-take-aways
robin, every time Amarin releases some BS statement the stock goes down.
birdrock, so the #1 PR firm gets paid a handsome sum to promote Amarins' lies. I hope Marjac will be ready when the time comes to sue Amarin when all the pumping lies don't come to fruition.
I can guarantee you that there will be zero revenues from all the bloviations about EU being a billion dollar endeavor. Maybe in 2025, just like China will be approved any day now oh and wow they have approval Puerto Rico why doesn't anyone call them out on that BS. LOL
they are desperate.
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
GLOBENEWSWIRE 12:34 PM ET 2/16/2023
Symbol Last Price Change
AMRN 1.875up -0.025 (-1.3158%)
QUOTES AS OF 12:34:37 PM ET 02/16/2023
Independent Report Acknowledges That Sarissa’s Campaign to Remove Amarin’s Chairman and De Facto Seize Board Control Would be Detrimental to Shareholder Value
Board Urges Shareholders to Follow ISS and Glass Lewis's Recommendations and Vote “AGAINST” All of Sarissa’s Proposals on the WHITE Proxy Card
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) (“Amarin” or the “Company”) today announced that the leading independent proxy advisory firm, Institutional Shareholder Services (“ISS”), has recommended that shareholders vote “AGAINST” all of Sarissa’s proposals on the WHITE proxy card at the upcoming General Meeting of Shareholders, scheduled for February 28, 2023.
In its February 16, 2023, report, ISS determined that Sarissa’s campaign is nothing more than a transparent attempt to de facto seize control of the Board by removing Amarin’s new Chairman, Per Wold-Olsen, and installing seven of its underqualified individuals. ISS joins Glass Lewis in highlighting that Sarissa has failed to make a compelling case for change and recommending shareholders vote “AGAINST” the removal of Per Wold-Olsen and “AGAINST” the election of every Sarissa nominee. ISS stated1:
“The board has appropriately refreshed itself and the company's positioning for commercial success appears to be improving. [Sarissa] has not presented convincing criticisms in either of these areas. As such, [Sarissa] has not made a compelling case for change.”
“The company's strategic turn and operational execution since the appointment of Mikhail as CEO are particularly instructive. Quarterly revenue has stabilized, and the company has generated a small positive adjusted cash flow over the past two quarters... They nonetheless represent tangible steps forward that have clearly improved the company's position, and suggest that the company's current strategy is a credible path forward.”
“The board's refreshment then, appears to have been proactive, thorough, and appropriate for the company's ongoing repositioning.”
“…contrary to the [Sarissa’s] assertion about unsustainable cash burn, has been successful in stabilizing its cash levels over the past three quarters.”
“… the underperformance since Mikhail took over is not necessarily a surprise, as the value of the company now primarily depends on the success of commercialization efforts in Europe, which remain in early stages.”
“…the reason for this expenditure of shareholder effort comes mainly as a result of the number and degree of the company's positive actions during this period of time, and not from a lack of clarity in shareholder communication.”
Commenting on ISS and Glass Lewis’s recommendations, the Amarin Board of Directors (the “Board”) issued the following statement:
ISS and Glass Lewis rightfully highlight that at a time when Amarin(AMRN) needs to be laser focused on execution, nearly doubling the size of the Board with underqualified individuals will impede progress and be detrimental to shareholder value.
In its report, ISS recognizes Sarissa’s transparent tactic to maximize the size of the Board is a de facto method to seize control of the Board. Sarissa’s only “strategic idea” is one the Board has already considered and determined would destroy shareholder value. Sarissa continues to prove it fundamentally does not understand our business and its slate falls woefully short on the critical expertise Amarin(AMRN) needs today.
The Board is undertaking a deliberate, thoughtful and independent refreshment process and has been reconstituted with approximately 70% new independent directors appointed in 2022. This Board has taken meaningful and proactive action to get the Company on solid footing, improve operational and financial results and instill a purpose-built Board and leadership team. As a result of these actions, Amarin(AMRN) has made substantial early progress on its new European and International commercial strategy, is on track to exceed its $100 million annual cost savings plan and primed to capture a multi-billion-dollar market opportunity.
Amarin (AMRN) has a world-class Board with the expertise needed to oversee continued progress of the Company’s transformation plan. We are confident their skillsets outmatch Sarissa’s slate in every critical area. Mr. Wold-Olsen is one of the most well-respected international healthcare executives with a demonstrated ability to transform companies, and his track record of successful product launches is undisputed. Since Mr. Wold-Olsen’s appointment to the Board in January 2022 and subsequently his appointment as Chairman in May 2022, he has demonstrated steadfast leadership and his contributions to Amarin(AMRN) have been far-reaching from pricing negotiations, launch activities, cost containment plans and Board refreshment.
We strongly recommend that shareholders consider the facts and vote “AGAINST” Sarissa’s proposals on the WHITE proxy card today.
Amarin (AMRN) reminds shareholders that every vote is important, no matter how many or few shares it represents. Shareholders are urged to discard any blue proxy materials and to only vote using the WHITE proxy card. Shareholders can switch their vote at any time by simply voting on the WHITE proxy card “AGAINST” all of Sarissa’s harmful proposals. Only the latest-dated proxy counts.
Amarin (AMRN) shareholders of record as of January 23, 2023, are entitled to vote at the General Meeting. For ADS holders, the deadline to submit votes is 3 PM GMT (10 AM ET) on February 22, 2023, and for holders of ordinary shares, the deadline is 3 PM GMT (10 AM ET) on February 24, 2023.
Amarin (AMRN) shareholders who need assistance in voting their shares may call Amarin’s proxy solicitors, Morrow Sodali at (800) 662-5200 (toll-free) or (203) 658-9400 (collect) or Okapi Partners at (844) 343-2625 (toll-free) or (212) 297-0720 (international).
Additional materials regarding the Board of Directors’ recommendations for the General Meeting can be found at www.voteamarin.com.
Advisors
J.P. Morgan is acting as financial advisor. Ropes & Gray LLP and Goodwin Procter LLP are acting as legal advisors to the Company.
About Amarin(AMRN)
Amarin (AMRN) is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin(AMRN) has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to U.S. federal securities law. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin(AMRN) can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2021, and Amarin’s quarterly reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022, and September 30, 2022, and its other filings. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin(AMRN) undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin(AMRN) may enter into, amend or terminate.
Amarin Contact Information
Investor Inquiries:
Lisa DeFrancesco
Investor Relations Amarin Corporation plc
investor.relations@amarincorp.com (investor inquiries)
duke, you forgot another lie LTRO said in his post that Denner is dealing with Russian dirty money. That was and is a total lie. LTRO assumed this because Denner had been mentioned in some rag publication along with the Russian oligarch's name.
Defamation, character assassination.